COCRYSTAL PHARMA, INC. Gain (Loss) on Derivative Instruments, Net, Pretax
COCRYSTAL PHARMA, INC. (COCP) reported Gain (Loss) on Derivative Instruments, Net, Pretax of $2.60 million for the 12-month period ending 2016-12-31, per its 10-K filed 2017-03-31.
Discontinued › Income Statement › Other Income
us-gaap:GainLossOnDerivativeInstrumentsNetPretax · last filed 2017-03-31
- COCRYSTAL PHARMA, INC. gain (loss) on derivative instruments, net, pretax for fiscal 2016 was $2.60M.
- COCRYSTAL PHARMA, INC. gain (loss) on derivative instruments, net, pretax for fiscal 2015 was -$9.92M, a 273.05% decline from fiscal 2014.
- COCRYSTAL PHARMA, INC. gain (loss) on derivative instruments, net, pretax for fiscal 2014 was $5.73M, a 2884.38% increase from fiscal 2013.
- COCRYSTAL PHARMA, INC. gain (loss) on derivative instruments, net, pretax for fiscal 2013 was $192.00K.
| Period end | Gain (Loss) on Derivative Instruments, Net, Pretax 12 month |
|---|---|
| 2016-12-31 | $2.60M 10-K · filed 2017-03-31 |
| 2015-12-31 | -$9.92M 10-K · filed 2017-03-31 |
| 2014-12-31 | $5.73M 10-K · filed 2017-03-31 |
| 2013-12-31 | $192.00K 10-K · filed 2015-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |